Skip to Main Content

Scott Huntington

MD, MPH, MSc
Associate Professor of Internal Medicine (Hematology); Medical Director, Hematology Outpatient Program

Contact Information

Scott Huntington, MD, MPH, MSc

Research Summary

With the rapid evolution of cancer diagnostics and therapeutics, cancer care is increasingly complex. Dr. Huntington draws from his unique combination of clinical and health services research training to lead studies that aim to establish an evidence base enabling high quality patient-centered care. His research has leveraged large real-world data, patient-reported outcomes, and economic modeling to address critical questions facing patients with hematologic malignancies.

In addition to his health services research, Dr. Huntington is a dedicated clinical investigator focused on bringing novel therapeutics and innovative clinical trials to patients with lymphoma treated across the Smilow Cancer Center network.


Coauthors

Research Interests

Hematologic Diseases; Insurance; Lymphoma

Public Health Interests

Health Insurance

Selected Publications

  • Cost-Effectiveness of Azacitidine and Ivosidenib in Newly Diagnosed Older, Intensive Chemotherapy-Ineligible Patients with IDH1 -Mutant Acute Myeloid LeukemiaBewersdorf J, Patel K, Goshua G, Shallis R, Podoltsev N, Stahl M, Stempel J, Stein E, Huntington S, Zeidan A. Cost-Effectiveness of Azacitidine and Ivosidenib in Newly Diagnosed Older, Intensive Chemotherapy-Ineligible Patients with IDH1 -Mutant Acute Myeloid Leukemia Blood 2022, 140: 319-321. DOI: 10.1182/blood-2022-158465.
  • Total Costs of Care during Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: A Large Private Insurance Claim-Based AnalysisDi M, Long J, Isufi I, Foss F, Seropian S, Gross C, Huntington S. Total Costs of Care during Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: A Large Private Insurance Claim-Based Analysis Blood 2022, 140: 10818-10819. DOI: 10.1182/blood-2022-164915.
  • Real-World Practice Patterns and Outcomes Following Bruton Tyrosine Kinase Inhibitors (BTKi) in Older Patients with Mantle Cell Lymphoma (MCL): A Population-Based AnalysisDi M, Long J, Kothari S, Sethi T, Zeidan A, Podoltsev N, Shallis R, Wang R, Stempel J, Ma X, Huntington S. Real-World Practice Patterns and Outcomes Following Bruton Tyrosine Kinase Inhibitors (BTKi) in Older Patients with Mantle Cell Lymphoma (MCL): A Population-Based Analysis Blood 2022, 140: 10904-10906. DOI: 10.1182/blood-2022-164959.
  • Second Malignancies Among Older Patients with Classical Myeloproliferative Neoplasms Treated with RuxolitinibStempel J, Wang R, Shallis R, Huntington S, Zeidan A, Neparidze N, Di M, Ma X, Podoltsev N. Second Malignancies Among Older Patients with Classical Myeloproliferative Neoplasms Treated with Ruxolitinib Blood 2022, 140: 11004-11006. DOI: 10.1182/blood-2022-165156.
  • Treatment Patterns of Follicular Lymphoma in the United States: A Claims AnalysisHuntington S, Appukkuttan S, Wang W, Du Y, Hopson S, Babajanyan S. Treatment Patterns of Follicular Lymphoma in the United States: A Claims Analysis Journal Of Health Economics And Outcomes Research 2022, 115-122. DOI: 10.36469/jheor.2022.38070.
  • Poster: CLL-410 Adherence and Discontinuation Among Medicare Beneficiaries Initiating Venetoclax versus BTKis for Relapsed/Refractory Chronic Lymphocytic LeukemiaHuntington S, Manzoor B, Puckett J, Kamal-Bahl S, Alhasani H, Ravelo A, Fuldeore M, Doshi J. Poster: CLL-410 Adherence and Discontinuation Among Medicare Beneficiaries Initiating Venetoclax versus BTKis for Relapsed/Refractory Chronic Lymphocytic Leukemia Clinical Lymphoma Myeloma & Leukemia 2022, 22: s143. DOI: 10.1016/s2152-2650(22)00867-9.
  • CLL-410 Adherence and Discontinuation Among Medicare Beneficiaries Initiating Venetoclax versus BTKis for Relapsed/Refractory Chronic Lymphocytic LeukemiaHuntington S, Manzoor B, Puckett J, Kamal-Bahl S, Alhasani H, Ravelo A, Fuldeore M, Doshi J. CLL-410 Adherence and Discontinuation Among Medicare Beneficiaries Initiating Venetoclax versus BTKis for Relapsed/Refractory Chronic Lymphocytic Leukemia Clinical Lymphoma Myeloma & Leukemia 2022, 22: s277-s278. DOI: 10.1016/s2152-2650(22)01345-3.
  • Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: A population-based analyses.Di M, Long J, Long J, Kothari S, Sethi T, Zeidan A, Podoltsev N, Shallis R, Wang R, Ma X, Huntington S. Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: A population-based analyses. Journal Of Clinical Oncology 2022, 40: 7554-7554. DOI: 10.1200/jco.2022.40.16_suppl.7554.
  • Perceptions of Transfusion Access and Hospice Among Patients with Advanced Hematologic Malignancies (RP525)Odejide O, Huntington S, Hurley S, Kaufman R, Shi E, Johnson K, Tulsky J, Abel G. Perceptions of Transfusion Access and Hospice Among Patients with Advanced Hematologic Malignancies (RP525) Journal Of Pain And Symptom Management 2022, 63: 1111-1112. DOI: 10.1016/j.jpainsymman.2022.04.091.
  • 168 Impact of Post-Remission Consolidation Therapy on Outcomes of Haploidentical Hematopoietic Cell Transplantation for Acute Myelogenous LeukemiaMirza A, Byrne M, Huntington S, Shallis R, Zeidan A, Foss F, Isufi I, Podoltsev N, Engelhardt B, Kassim A, Savani B, Dholaria B, Jayani R, Perrault S, Schiffer M, Seropian S, Gowda L. 168 Impact of Post-Remission Consolidation Therapy on Outcomes of Haploidentical Hematopoietic Cell Transplantation for Acute Myelogenous Leukemia Transplantation And Cellular Therapy 2022, 28: s139-s140. DOI: 10.1016/s2666-6367(22)00329-3.
  • Cost-Effectiveness of Liposomal Cytarabine-Daunorubicin (CPX-351) Compared to Conventional Cytarabine-Daunorubicin Chemotherapy in Acute Myeloid LeukemiaBewersdorf J, Goshua G, Patel K, Shallis R, Podoltsev N, Huntington S, Zeidan A. Cost-Effectiveness of Liposomal Cytarabine-Daunorubicin (CPX-351) Compared to Conventional Cytarabine-Daunorubicin Chemotherapy in Acute Myeloid Leukemia Blood 2021, 138: 113-113. DOI: 10.1182/blood-2021-144992.
  • Survival of Mantle Cell Lymphoma in the Era of Bruton Tyrosine Kinase Inhibitors: A Population-Based AnalysisDi M, Cui C, Kothari S, Zeidan A, Podoltsev N, Neparidze N, Shallis R, Wang R, Ma X, Huntington S. Survival of Mantle Cell Lymphoma in the Era of Bruton Tyrosine Kinase Inhibitors: A Population-Based Analysis Blood 2021, 138: 182-182. DOI: 10.1182/blood-2021-146417.
  • Changes in Multiple Myeloma Treatment Patterns during the Early COVID-19 Pandemic PeriodNeparidze N, Wang R, Zeidan A, Podoltsev N, Shallis R, Ma X, Davidoff A, Huntington S. Changes in Multiple Myeloma Treatment Patterns during the Early COVID-19 Pandemic Period Blood 2021, 138: 4092-4092. PMCID: PMC8701553, DOI: 10.1182/blood-2021-148998.
  • Contemporary "Real World" Molecular Testing and Tyrosine Kinase Inhibitor Adherence Patterns Among Older Pts with Chronic Myeloid Leukemia in the United StatesShallis R, Wang R, Zeidan A, Huntington S, Neparidze N, Di M, Ma X, Podoltsev N. Contemporary "Real World" Molecular Testing and Tyrosine Kinase Inhibitor Adherence Patterns Among Older Pts with Chronic Myeloid Leukemia in the United States Blood 2021, 138: 282-282. DOI: 10.1182/blood-2021-151066.
  • Impact of the COVID-19 Pandemic on in-Person Visit Rates Among Patients with Hematologic Malignancies in the United StatesGoyal G, Lau K, Wang X, Davidoff A, Huntington S, Jamy O, Calip G, Shah H, Stephens D, Miksad R, Parikh R, Takvorian S, Neparidze N, Seymour E. Impact of the COVID-19 Pandemic on in-Person Visit Rates Among Patients with Hematologic Malignancies in the United States Blood 2021, 138: 1930-1930. PMCID: PMC8701834, DOI: 10.1182/blood-2021-153625.
  • Racial Disparities in Telemedicine Uptake during the COVID-19 Pandemic Among Patients with Hematologic Malignancies in the United StatesNeparidze N, Lau K, Wang X, Davidoff A, Huntington S, Jamy O, Calip G, Shah H, Stephens D, Miksad R, Parikh R, Takvorian S, Goyal G, Seymour E. Racial Disparities in Telemedicine Uptake during the COVID-19 Pandemic Among Patients with Hematologic Malignancies in the United States Blood 2021, 138: 1973-1973. PMCID: PMC8701527, DOI: 10.1182/blood-2021-153787.
  • Efficacy and Safety of Ublituximab in Combination with Umbralisib (U2) in Patients with Chronic Lymphocytic Leukemia (CLL) By Treatment Status: A Sub-Analysis of the Phase 3 Unity-CLL StudyJacobs R, Jurczak W, Flinn I, Grosicki S, Giannopoulos K, Wróbel T, Zafar S, Cultrera J, Kambhampati S, Danilov A, Burke J, Goldschmidt J, Beach D, Huntington S, Pinilla Ibarz J, Sharman J, Siddiqi T, Brander D, Shadman M, Pagel J, Dlugosz-Danecka M, Ghosh N, Kolibaba K, Sportelli P, Miskin H, O'Connor O, Weiss M, Gribben J. Efficacy and Safety of Ublituximab in Combination with Umbralisib (U2) in Patients with Chronic Lymphocytic Leukemia (CLL) By Treatment Status: A Sub-Analysis of the Phase 3 Unity-CLL Study Blood 2021, 138: 3726-3726. DOI: 10.1182/blood-2021-147460.
  • First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with HclPark J, Winer E, Huntington S, von Keudell G, Vemuri S, Shukla M, Kinoshita J, Falco V, Gore S, Stone R, Abdel-Wahab O, Tallman M. First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl Blood 2021, 138: 43-43. DOI: 10.1182/blood-2021-151074.
  • Favorable Outcomes for Patients Treated with U2 with Co-Morbidities or Concomitant Medications: A Retrospective Analysis of Unity-CLL Phase 3 TrialPinilla Ibarz J, Jurczak W, Kambhampati S, Lech Maranda E, Wróbel T, Sharman J, Zafar S, Hoffmann M, Huntington S, Jacobs R, Bairey O, Rowland C, Miskin H, Sportelli P, Weiss M, O'Connor O, Flinn I. Favorable Outcomes for Patients Treated with U2 with Co-Morbidities or Concomitant Medications: A Retrospective Analysis of Unity-CLL Phase 3 Trial Blood 2021, 138: 3748-3748. DOI: 10.1182/blood-2021-151292.
  • Perceptions of Hospice and Transfusion Access Among Patients with Advanced Blood Cancers: Results from a Best-Worst Scaling SurveyOdejide O, Huntington S, Shi E, Johnson K, Tulsky J, Abel G. Perceptions of Hospice and Transfusion Access Among Patients with Advanced Blood Cancers: Results from a Best-Worst Scaling Survey Blood 2021, 138: 3020-3020. DOI: 10.1182/blood-2021-153304.
  • Perceptions of Prognosis Among Patients with Advanced Hematologic MalignanciesOdejide O, Huntington S, Kuczmarski T, Shi E, Tulsky J, Abel G. Perceptions of Prognosis Among Patients with Advanced Hematologic Malignancies Blood 2021, 138: 4026-4026. DOI: 10.1182/blood-2021-153361.
  • Primary anti-infective prophylaxis during routine treatment of lymphoma in the United States: A large real-world cohort analysis.Di M, Soulos P, Huntington S. Primary anti-infective prophylaxis during routine treatment of lymphoma in the United States: A large real-world cohort analysis. Journal Of Clinical Oncology 2021, 39: 268-268. DOI: 10.1200/jco.2020.39.28_suppl.268.
  • Racial, ethnic, and socioeconomic disparities in treatment outcomes in patients (pts) with diffuse large B-cell lymphoma (DLBCL): A U.S. real-world study using a de-identified electronic health record (EHR)-derived database.Jin Y, Li J, Mun Y, Masaquel A, Hu S, Biondo J, Huntington S. Racial, ethnic, and socioeconomic disparities in treatment outcomes in patients (pts) with diffuse large B-cell lymphoma (DLBCL): A U.S. real-world study using a de-identified electronic health record (EHR)-derived database. Journal Of Clinical Oncology 2021, 39: e18514-e18514. DOI: 10.1200/jco.2021.39.15_suppl.e18514.
  • Bundling cancer subtypes in value-based care: A pilot analysis of lymphoma episodes in the Oncology Care Model.Yue A, Chaudhry B, Schleicher S, Huntington S, Lyss A, Connor N, Tran L, Adelson K. Bundling cancer subtypes in value-based care: A pilot analysis of lymphoma episodes in the Oncology Care Model. Journal Of Clinical Oncology 2021, 39: e18850-e18850. DOI: 10.1200/jco.2021.39.15_suppl.e18850.
  • Cost-Effectiveness of Once-Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice-Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple MyelomaPatel K, Parker T, Di M, Bar N, Huntington S, Giri S. Cost-Effectiveness of Once-Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice-Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma Blood 2020, 136: 51-52. DOI: 10.1182/blood-2020-141972.
  • Practice Patterns and Real-Life Outcomes for Patients with Acute Promyelocytic LeukemiaBewersdorf J, Prozora S, Wang R, Podoltsev N, Shallis R, Huntington S, Neparidze N, Ma X, Gore S, Zeidan A, Davidoff A. Practice Patterns and Real-Life Outcomes for Patients with Acute Promyelocytic Leukemia Blood 2020, 136: 21-22. DOI: 10.1182/blood-2020-136983.
  • Predictors of Tyrosine Kinase Inhibitor Use Among Older Patients with Chronic Myeloid Leukemia in the United StatesWang R, Shallis R, Bewersdorf J, Zeidan A, Huntington S, Ma X, Podoltsev N. Predictors of Tyrosine Kinase Inhibitor Use Among Older Patients with Chronic Myeloid Leukemia in the United States Blood 2020, 136: 13-14. DOI: 10.1182/blood-2020-139468.
  • Contemporary Practice Patterns of Tyrosine Kinase Inhibitor Use Among Older Patients with Chronic Myeloid Leukemia in the United StatesShallis R, Wang R, Bewersdorf J, Zeidan A, Huntington S, Davidoff A, Ma X, Podoltsev N. Contemporary Practice Patterns of Tyrosine Kinase Inhibitor Use Among Older Patients with Chronic Myeloid Leukemia in the United States Blood 2020, 136: 44-45. DOI: 10.1182/blood-2020-139531.
  • Oncologist Sub-Specialization, Care Setting, and Multiple Myeloma Treatment and OutcomesDavidoff A, Long J, Neparidze N, Bewersdorf J, Shallis R, Podoltsev N, Wang R, Gore S, Zeidan A, Huntington S. Oncologist Sub-Specialization, Care Setting, and Multiple Myeloma Treatment and Outcomes Blood 2020, 136: 2-3. DOI: 10.1182/blood-2020-140728.
  • Weekly Dosing Schedule of Brentuximab Vedotin in Mycosis Fungoides/Sezary Syndrome and Aggressive T Cell LymphomasLee M, Schiffer M, Isufi I, Huntington S, Xu M, Seropian S, Gowda L, Kothari S, Girardi M, Foss F. Weekly Dosing Schedule of Brentuximab Vedotin in Mycosis Fungoides/Sezary Syndrome and Aggressive T Cell Lymphomas Blood 2020, 136: 21-22. DOI: 10.1182/blood-2020-139790.
  • Real-World IgG Testing Frequency and Characteristics Associated with Hypogammaglobulinemia after Anti-CD20 Exposure in Patients with Chronic Lymphocytic Leukemia (CLL)Hooley I, Maignan K, Jacob A, Medina A, Benderoff L, Chen R, Huntington S. Real-World IgG Testing Frequency and Characteristics Associated with Hypogammaglobulinemia after Anti-CD20 Exposure in Patients with Chronic Lymphocytic Leukemia (CLL) Blood 2020, 136: 43-44. DOI: 10.1182/blood-2020-137094.
  • A Once Daily, Oral, Triple Combination of BTK Inhibitor, mTOR Inhibitor and IMiD for Treatment of Relapsed/Refractory Richter's Transformation and De Novo Diffuse Large B-Cell LymphomaMato A, Schuster S, Foss F, Isufi I, Kothari S, Ding W, Brander D, Sitlinger A, Rosenthal A, Leis J, Tun H, Kennard K, Nelson A, Falco V, Komari C, Koehler A, Stowe R, He W, Kearney A, Gui M, McKinlay T, Roeker L, Thompson M, Huntington S. A Once Daily, Oral, Triple Combination of BTK Inhibitor, mTOR Inhibitor and IMiD for Treatment of Relapsed/Refractory Richter's Transformation and De Novo Diffuse Large B-Cell Lymphoma Blood 2020, 136: 21-22. DOI: 10.1182/blood-2020-138896.
  • Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL StudyGribben J, Jurczak W, Jacobs R, Grosicki S, Giannopoulos K, Wrobel T, Zafar S, Cultrera J, Kambhampati S, Danilov A, Burke J, Goldschmidt J, Beach D, Huntington S, Pinilla Ibarz J, Sharman J, Siddiqi T, Brander D, Pagel J, Kolibaba K, Dlugosz-Danecka M, Ghosh N, Sportelli P, Miskin H, O'Connor O, Weiss M, Flinn I. Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study Blood 2020, 136: 37-39. DOI: 10.1182/blood-2020-134783.
  • CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic InstitutionsOrellana-Noia V, Reed D, Sen J, Barlow C, Malecek M, Kahl B, Spinner M, Advani R, Voorhees T, Snow A, Grover N, Ayers A, Romancik J, Liu Y, Huntington S, Chavez J, Saeed H, Lazaryan A, Raghunathan V, Spurgeon S, Ollila T, Del Prete C, Olszewski A, Ayers E, Landsburg D, Echalier B, Lee J, Kamdar M, Caimi P, Fu T, Liu J, David K, Alharthy H, Law J, Karmali R, Shah H, Stephens D, Major A, Rojek A, Smith S, Yellala A, Kallam A, Nakhoda S, Khan N, Cohen J, Portell C. CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions Blood 2020, 136: 27-28. DOI: 10.1182/blood-2020-134798.
  • Worldwide Examination of Patients with CLL Hospitalized for COVID-19Roeker L, Scarfo L, Chatzikonstantinou T, Abrisqueta P, Eyre T, Cordoba R, Muntañola Prat A, Villacampa G, Leslie L, Koropsak M, Quaresmini G, Allan J, Furman R, Bhavsar E, Pagel J, Hernandez-Rivas J, Patel K, Motta M, Bailey N, Miras F, Lamanna N, Alonso R, Osorio-Prendes S, Vitale C, Kamdar M, Baltasar P, Österborg A, Hanson L, Baile M, Rodríguez-Hernández I, Valenciano S, Popov V, Barez Garcia A, Alfayate A, Oliveira A, Eichhorst B, Quaglia F, Reda G, Lopez Jimenez J, Varettoni M, Marchetti M, Romero P, Riaza Grau R, Munir T, Zabalza A, Janssens A, Niemann C, Perini G, Delgado J, Yanez San Segundo L, Gómez Roncero M, Wilson M, Patten P, Marasca R, Iyengar S, Seddon A, Torres A, Ferrari A, Cuéllar-García C, Wojenski D, El-Sharkawi D, Itchaki G, Parry H, Mateos-Mazón J, Martinez-Calle N, Ma S, Naya D, Van Der Spek E, Seymour E, Gimeno Vázquez E, Rigolin G, Mauro F, Walter H, Labrador J, De Paoli L, Laurenti L, Ruiz E, Levin M, Šimkovič M, Špaček M, Andreu R, Walewska R, Perez-Gonzalez S, Sundaram S, Wiestner A, Cuesta A, Broom A, Kater A, Muiña B, Velasquez C, Ujjani C, Seri C, Antic D, Bron D, Vandenberghe E, Chong E, Lista E, García F, Del Poeta G, Ahn I, Pu J, Brown J, Soler Campos J, Malerba L, Trentin L, Orsucci L, Farina L, Villalon L, Vidal M, Sanchez M, Terol M, De Paolis M, Gentile M, Davids M, Shadman M, Yassin M, Foglietta M, Jaksic O, Sportoletti P, Barr P, Ramos R, Santiago R, Ruchlemer R, Kersting S, Huntington S, Herold T, Herishanu Y, Thompson M, Lebowitz S, Ryan C, Jacobs R, Portell C, Isaac K, Rambaldi A, Nabhan C, Brander D, Montserrat E, Rossi G, Garcia-Marco J, Coscia M, Malakhov N, Fernandez-Escalada N, Skånland S, Coombs C, Ghione P, Schuster S, Foà R, Cuneo A, Bosch F, Stamatopoulos K, Ghia P, Mato A, Patel M. Worldwide Examination of Patients with CLL Hospitalized for COVID-19 Blood 2020, 136: 45-49. PMCID: PMC8330255, DOI: 10.1182/blood-2020-136408.
  • Multiple myeloma (MM) therapy within a Medicare-insured patient population: Role of care setting and oncologist sub-specialization in hematologic malignancies.Davidoff A, Long J, Huntington S. Multiple myeloma (MM) therapy within a Medicare-insured patient population: Role of care setting and oncologist sub-specialization in hematologic malignancies. Journal Of Clinical Oncology 2020, 38: 38-38. DOI: 10.1200/jco.2020.38.29_suppl.38.
  • Multiple myeloma (MM) therapy within a Medicare insured patient population: Role of initial care setting and socioeconomic status.Davidoff A, Long J, Bewersdorf J, Shallis R, Zeidan A, Podoltsev N, Wang R, Gore S, Giri S, Neparidze N, Huntington S. Multiple myeloma (MM) therapy within a Medicare insured patient population: Role of initial care setting and socioeconomic status. Journal Of Clinical Oncology 2020, 38: e19057-e19057. DOI: 10.1200/jco.2020.38.15_suppl.e19057.
  • PCN234 TREATMENT PATTERNS OF FOLLICULAR LYMPHOMA PATIENTS: A CLAIMS ANALYSISAppukkuttan S, Wang W, Babajanyan S, Hopson S, Du Y, Huntington S. PCN234 TREATMENT PATTERNS OF FOLLICULAR LYMPHOMA PATIENTS: A CLAIMS ANALYSIS Value In Health 2020, 23: s64. DOI: 10.1016/j.jval.2020.04.1705.
  • Clinical Outcomes of Patients (pts) with TP53-Mutated Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS): A Single Center ExperienceBewersdorf J, Shallis R, Gowda L, Hager K, Podoltsev N, Gore S, Prebet T, Halene S, Isufi I, Foss F, Huntington S, Kim T, Pillai M, Parker T, Neparidze N, Bar N, Seropian S, Siddon A, Zeidan A. Clinical Outcomes of Patients (pts) with TP53-Mutated Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS): A Single Center Experience Blood 2019, 134: 5173-5173. DOI: 10.1182/blood-2019-127162.
  • Isolated Trisomy 11 in Patients with Myeloid Malignancies - Is the Prognosis Not As Grim As Previously Thought?Bewersdorf J, Shallis R, Diadamo A, Gowda L, Podoltsev N, Gore S, Prebet T, Halene S, Isufi I, Foss F, Huntington S, Kim T, Pillai M, Parker T, Neparidze N, Bar N, Seropian S, Siddon A, Zeidan A. Isolated Trisomy 11 in Patients with Myeloid Malignancies - Is the Prognosis Not As Grim As Previously Thought? Blood 2019, 134: 5174-5174. DOI: 10.1182/blood-2019-127277.
  • Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center ExperienceShallis R, Bewersdorf J, Gowda L, Podoltsev N, Prebet T, Gore S, Halene S, Isufi I, Foss F, Huntington S, Kim T, Pillai M, Parker T, Neparidze N, Bar N, Seropian S, Zeidan A. Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center Experience Blood 2019, 134: 1330-1330. DOI: 10.1182/blood-2019-127422.
  • The Impact of the 2011 European Leukemianet (ELN) Guidelines for Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms on Therapeutic Phlebotomy and Hydroxyurea Use in Patients with Polycythemia Vera and Essential ThrombocythemiaPodoltsev N, Wang R, Shallis R, Huntington S, Zeidan A, Gore S, Davidoff A, Ma X. The Impact of the 2011 European Leukemianet (ELN) Guidelines for Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms on Therapeutic Phlebotomy and Hydroxyurea Use in Patients with Polycythemia Vera and Essential Thrombocythemia Blood 2019, 134: 2125-2125. DOI: 10.1182/blood-2019-127563.
  • Clinical Effectiveness of Hypomethylating Agents (HMAs) and Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Population-Based Study in the United States (US)Wang X, Wang R, Zhang C, Zeidan A, Podoltsev N, Huntington S, Gore S, Davidoff A, Ma X. Clinical Effectiveness of Hypomethylating Agents (HMAs) and Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Population-Based Study in the United States (US) Blood 2019, 134: 4748-4748. DOI: 10.1182/blood-2019-128821.
  • Patterns of Care and Clinical Outcomes with 7+3 Induction Chemotherapy for Patients (pts) with Acute Myeloid Leukemia (AML) in the United States (US): A Large Population-Based StudyZeidan A, Podoltsev N, Wang X, Bewersdorf J, Shallis R, Huntington S, Neparidze N, Giri S, Gore S, Ma X, Davidoff A, Wang R. Patterns of Care and Clinical Outcomes with 7+3 Induction Chemotherapy for Patients (pts) with Acute Myeloid Leukemia (AML) in the United States (US): A Large Population-Based Study Blood 2019, 134: 116-116. DOI: 10.1182/blood-2019-126643.
  • Clinical Outcomes of Older Patients (pts) with Acute Myeloid Leukemia (AML) Receiving Hypomethylating Agents (HMAs): A Large Population-Based Study in the United StatesZeidan A, Wang R, Wang X, Shallis R, Podoltsev N, Bewersdorf J, Huntington S, Neparidze N, Giri S, Gore S, Davidoff A, Ma X. Clinical Outcomes of Older Patients (pts) with Acute Myeloid Leukemia (AML) Receiving Hypomethylating Agents (HMAs): A Large Population-Based Study in the United States Blood 2019, 134: 646-646. DOI: 10.1182/blood-2019-127398.
  • Incidence and Risk Factors of Second Malignancies Among Medicare Beneficiaries with Newly-Diagnosed Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms Receiving Cytoreductive Therapy with HydroxyureaWang R, Shallis R, Huntington S, Zeidan A, Gore S, Davidoff A, Ma X, Podoltsev N. Incidence and Risk Factors of Second Malignancies Among Medicare Beneficiaries with Newly-Diagnosed Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms Receiving Cytoreductive Therapy with Hydroxyurea Blood 2019, 134: 330-330. DOI: 10.1182/blood-2019-127568.
  • AG-636 for the Treatment of Adults with Advanced Lymphoma: Initiation of a Phase 1 Clinical StudyHuntington S, Kallam A, Basile F, Ulanet D, Xu H, Yin F, Mobilia M, Cooper M, Shah B, Leonard J, von Keudell G, Gopal A. AG-636 for the Treatment of Adults with Advanced Lymphoma: Initiation of a Phase 1 Clinical Study Blood 2019, 134: 1286-1286. DOI: 10.1182/blood-2019-123420.
  • Anti-CD47 Antibody, CC-90002, in Combination with Rituximab in Subjects with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)Abrisqueta P, Sancho J, Cordoba R, Persky D, Andreadis C, Huntington S, Carpio C, Morillo Giles D, Wei X, Li Y, Zuraek M, Burgess M, Hege K, Martín A. Anti-CD47 Antibody, CC-90002, in Combination with Rituximab in Subjects with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL) Blood 2019, 134: 4089-4089. DOI: 10.1182/blood-2019-125310.
  • Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell TransplantationChandhok N, Huntington S, Isufi I, Gowda L, Xu M, Bar N, Seropian S, Foss F. Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation Blood 2019, 134: 4055-4055. DOI: 10.1182/blood-2019-128888.
  • Evaluation of Efficacy and Safety of Front-Line Regimens for the Treatment of Transplant Ineligible Patients with Multiple Myeloma: A Network Meta-Analysis of Phase 2/3 Randomized Controlled TrialsGiri S, Aryal M, Yu H, Grimshaw A, Pathak R, Huntington S, Dhakal B. Evaluation of Efficacy and Safety of Front-Line Regimens for the Treatment of Transplant Ineligible Patients with Multiple Myeloma: A Network Meta-Analysis of Phase 2/3 Randomized Controlled Trials Blood 2019, 134: 2188-2188. DOI: 10.1182/blood-2019-130389.
  • Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United StatesHuntington S, Soulos P, Barr P, Jacobs R, Lansigan F, Odejide O, Schwartzberg L, Davidoff A, Gross C. Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United States Blood 2019, 134: 797-797. DOI: 10.1182/blood-2019-122054.
  • A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxhs-12 (DTRM-12), in Combination with Everolimus and Pomalidomide in Patients with Relapsed/Refractory CLL, DLBCL or Other B-Cell LymphomasMato A, Schuster S, Foss F, Isufi I, Ding W, Brander D, Sitlinger A, Tun H, Alhaj Moustafa M, Kennard K, King C, Koehler A, Aitken C, He W, Kearney A, Gui M, Anderson B, Rosenthal A, Roeker L, Huntington S. A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxhs-12 (DTRM-12), in Combination with Everolimus and Pomalidomide in Patients with Relapsed/Refractory CLL, DLBCL or Other B-Cell Lymphomas Blood 2019, 134: 810-810. DOI: 10.1182/blood-2019-126192.
  • Chromosome 1 abnormalities and clinical outcomes in multiple myeloma in the era of novel agents.Giri S, Huntington S, Wang R, Zeidan A, Podoltsev N, Gore S, Ma X, Gross C, Davidoff A, Neparidze N. Chromosome 1 abnormalities and clinical outcomes in multiple myeloma in the era of novel agents. Journal Of Clinical Oncology 2019, 37: 8044-8044. DOI: 10.1200/jco.2019.37.15_suppl.8044.
  • PCN122 COST-EFFECTIVENESS OF A 24-MONTH FIXED DURATION OF VENETOCLAX IN COMBINATION WITH RITUXIMAB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA IN THE UNITED STATESHuntington S, Strunz-McKendry T, Masaquel A, Shapouri S, Sail K, Durno N, Mato A. PCN122 COST-EFFECTIVENESS OF A 24-MONTH FIXED DURATION OF VENETOCLAX IN COMBINATION WITH RITUXIMAB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA IN THE UNITED STATES Value In Health 2019, 22: s78-s79. DOI: 10.1016/j.jval.2019.04.246.
  • Does Provider Experience Treating Patients (pts) with Myelodysplastic Syndromes (MDS) Explain Duration of Hypomethylating Agent (HMA) Therapy and Overall Survival (OS)? A Large Population-Based AnalysisZeidan A, Hu X, Zhu W, Stahl M, Giri S, Huntington S, Wang R, Podoltsev N, Gore S, Ma X, Davidoff A. Does Provider Experience Treating Patients (pts) with Myelodysplastic Syndromes (MDS) Explain Duration of Hypomethylating Agent (HMA) Therapy and Overall Survival (OS)? A Large Population-Based Analysis Blood 2018, 132: 370-370. DOI: 10.1182/blood-2018-99-111052.
  • Association between Oncologist Ownership of Imaging Facilities and Utilization: An Analysis of Positron-Emission Tomography (PET) Use in Lymphoma Settings with Variable PET UtilityHuntington S, Zhu W, Hoag J, Wang R, Zeidan A, Giri S, Podoltsev N, Gore S, Ma X, Gross C, Davidoff A. Association between Oncologist Ownership of Imaging Facilities and Utilization: An Analysis of Positron-Emission Tomography (PET) Use in Lymphoma Settings with Variable PET Utility Blood 2018, 132: 3538-3538. DOI: 10.1182/blood-2018-99-115140.
  • Transfusion Independence in Lower-Risk, Non-del5(q) Myelodysplastic Syndromes (LR-MDS) Among Patients (pts) Initiating Hypomethylating Agents (HMAs) While Receiving Red Blood Cell (RBC) TransfusionsZeidan A, Zhu W, Wang R, Stahl M, Huntington S, Giri S, Podoltsev N, Gore S, Ma X, Davidoff A. Transfusion Independence in Lower-Risk, Non-del5(q) Myelodysplastic Syndromes (LR-MDS) Among Patients (pts) Initiating Hypomethylating Agents (HMAs) While Receiving Red Blood Cell (RBC) Transfusions Blood 2018, 132: 838-838. DOI: 10.1182/blood-2018-99-116497.
  • Use of Statins, Survival and Incidence of Thrombosis Among Older Adults with Essential Thrombocythemia: A Population-Based StudyPodoltsev N, Zhu M, Wang R, Zeidan A, Wang X, Huntington S, Giri S, Davidoff A, Gore S, Ma X. Use of Statins, Survival and Incidence of Thrombosis Among Older Adults with Essential Thrombocythemia: A Population-Based Study Blood 2018, 132: 4865-4865. DOI: 10.1182/blood-2018-99-119118.
  • Use of Statins, Survival and Incidence of Thrombosis Among Older Adults with Polycythemia Vera: A Population-Based StudyPodoltsev N, Zhu M, Wang R, Zeidan A, Wang X, Davidoff A, Huntington S, Giri S, Gore S, Ma X. Use of Statins, Survival and Incidence of Thrombosis Among Older Adults with Polycythemia Vera: A Population-Based Study Blood 2018, 132: 3580-3580. DOI: 10.1182/blood-2018-99-119272.
  • Racial Disparities in the Utilization of Recommended Supportive Care Among Patients with Multiple Myeloma in the United StatesGiri S, Zhu W, Wang R, Zeidan A, Podoltsev N, Gore S, Ma X, Davidoff A, Huntington S. Racial Disparities in the Utilization of Recommended Supportive Care Among Patients with Multiple Myeloma in the United States Blood 2018, 132: 978-978. DOI: 10.1182/blood-2018-99-119791.
  • Phase I Study of First-in-Class Oral Triplet Therapy DTRM-555 in Relapsed/Refractory Lymphoma Patients through Fixed-Dose Combination and Synthetic LethalityHuntington S, Schuster S, He W, Shen T, Walker H, Leary L, Boyhen K, Gill J, Chatburn E, Kennard K, Dwivedy Nasta S, Landsburg D, Porter D, Napier E, Hughes M, Latorre T, Walsh K, Dorsey C, Svoboda J, Addis V, Anderson B, Leblond E, Song Y, Zhu J, Deng L, Brander D, Ding W, Rosenthal A, Tun H, Mato A. Phase I Study of First-in-Class Oral Triplet Therapy DTRM-555 in Relapsed/Refractory Lymphoma Patients through Fixed-Dose Combination and Synthetic Lethality Blood 2018, 132: 5384-5384. DOI: 10.1182/blood-2018-99-112944.
  • Prognostic understanding in acute leukemia: Patient-physician differences.Shimer S, Canavan M, Capasso R, Gore S, Tannenbaum S, Babar T, Podoltsev N, Seropian S, Huntington S, Zeidan A, von Keudell G, Prebet T, Adelson K. Prognostic understanding in acute leukemia: Patient-physician differences. Journal Of Clinical Oncology 2018, 36: e22124-e22124. DOI: 10.1200/jco.2018.36.15_suppl.e22124.
  • Cost-effectiveness analysis of brentuximab vedotin with chemotherapy in newly diagnosed stage III/IV Hodgkin lymphoma.Huntington S, Von Keudell G, Davidoff A, Gross C, Prasad S. Cost-effectiveness analysis of brentuximab vedotin with chemotherapy in newly diagnosed stage III/IV Hodgkin lymphoma. Journal Of Clinical Oncology 2018, 36: 6609-6609. DOI: 10.1200/jco.2018.36.15_suppl.6609.
  • Impact of electronic decision support and targeted educational intervention to increase adherence with ASCO Choosing Wisely breast cancer staging guideline.Konuthula D, Canavan M, Huntington S, Strait M, Vega T, Framski K, Adelson K. Impact of electronic decision support and targeted educational intervention to increase adherence with ASCO Choosing Wisely breast cancer staging guideline. Journal Of Clinical Oncology 2018, 36: e18826-e18826. DOI: 10.1200/jco.2018.36.15_suppl.e18826.
  • Trends in utilization and in-hospital outcomes of high dose therapy and autologous stem cell transplantation among patients with AL amyloidosis in the United States.Giri S, Mehta K, Hoag J, Huntington S, Dhakal B. Trends in utilization and in-hospital outcomes of high dose therapy and autologous stem cell transplantation among patients with AL amyloidosis in the United States. Journal Of Clinical Oncology 2018, 36: e20000-e20000. DOI: 10.1200/jco.2018.36.15_suppl.e20000.
  • Relationship between Hospital Volume and Inpatient Mortality Among Patients Diagnosed with Thrombotic Thrombocytopenic Purpura (TTP) in the United StatesGiri S, Pathak R, Franklin R, Podoltsev N, Huntington S, Mehta K, Zeidan A. Relationship between Hospital Volume and Inpatient Mortality Among Patients Diagnosed with Thrombotic Thrombocytopenic Purpura (TTP) in the United States Blood 2017, 130: 675-675. DOI: 10.1182/blood.v130.suppl_1.675.675.
  • Hypomethylating agent (HMA) therapy use and survival in older patients with higher risk myelodysplastic syndromes (HR-MDS) in the United States (USA): A large population-based study.Zeidan A, Hu X, Long J, Wang R, Huntington S, Podoltsev N, Giri S, Stahl M, Gore S, Ma X, Davidoff A. Hypomethylating agent (HMA) therapy use and survival in older patients with higher risk myelodysplastic syndromes (HR-MDS) in the United States (USA): A large population-based study. Journal Of Clinical Oncology 2017, 35: 7057-7057. DOI: 10.1200/jco.2017.35.15_suppl.7057.
  • Physician volume and discontinuation of rituximab during lymphoma treatment.Huntington S, Long J, Hoag J, Wang R, Zeidan A, Giri S, Gore S, Ma X, Gross C, Davidoff A. Physician volume and discontinuation of rituximab during lymphoma treatment. Journal Of Clinical Oncology 2017, 35: 6593-6593. DOI: 10.1200/jco.2017.35.15_suppl.6593.
  • 121 Hypomethylating Agent Therapy Use and Survival in Older Patients with Higher Risk Myelodysplastic Syndromes in USA: A Large Population-Based StudyZeidan A, Hu X, Long J, Wang R, Huntington S, Podoltsev N, Giri S, Stahl M, Gore S, Ma X, Davidoff A. 121 Hypomethylating Agent Therapy Use and Survival in Older Patients with Higher Risk Myelodysplastic Syndromes in USA: A Large Population-Based Study Leukemia Research 2017, 55: s75-s76. DOI: 10.1016/s0145-2126(17)30234-5.
  • 32 Hypomethylating Agent Therapy use and Survival in Older Patients with Chronic Myelomonocytic Leukemia in USA: A Large Population-Based StudyZeidan A, Hu X, Long J, Wang R, Ma X, Podoltsev N, Huntington S, Gore S, Davidoff A. 32 Hypomethylating Agent Therapy use and Survival in Older Patients with Chronic Myelomonocytic Leukemia in USA: A Large Population-Based Study Leukemia Research 2017, 55: s20-s21. DOI: 10.1016/s0145-2126(17)30145-5.
  • Hypomethylating Agent Therapy and Survival Among Older Patients with Chronic Myelomonocytic Leukemia in the United States: A Large Population-Based StudyZeidan A, Hu X, Long J, Wang R, Huntington S, Podoltsev N, Gore S, Ma X, Davidoff A. Hypomethylating Agent Therapy and Survival Among Older Patients with Chronic Myelomonocytic Leukemia in the United States: A Large Population-Based Study Blood 2016, 128: 394-394. DOI: 10.1182/blood.v128.22.394.394.
  • Cost-Effectiveness Analysis of Consolidation with Brentuximab Vendotin Versus Active Surveillance in Individuals with High-Risk Hodgkin Lymphoma Undergoing High Dose Chemotherapy with Stem Cell RescueHui L, von Keudell G, Wang R, Zeidan A, Gore S, Ma X, Davidoff A, Huntington S. Cost-Effectiveness Analysis of Consolidation with Brentuximab Vendotin Versus Active Surveillance in Individuals with High-Risk Hodgkin Lymphoma Undergoing High Dose Chemotherapy with Stem Cell Rescue Blood 2016, 128: 1188-1188. DOI: 10.1182/blood.v128.22.1188.1188.
  • Evaluating the Economic Burden and Health Care Utilization Following First-Line Therapy for Diffuse Large B-Cell Lymphoma Patients in the US Medicare PopulationHuntington S, Keshishian A, Xie L, Baser O, McGuire M. Evaluating the Economic Burden and Health Care Utilization Following First-Line Therapy for Diffuse Large B-Cell Lymphoma Patients in the US Medicare Population Blood 2016, 128: 3574-3574. DOI: 10.1182/blood.v128.22.3574.3574.
  • Characterization of Real World Survival Outcomes Among Older Adults with Chronic Lymphocytic Leukemia Receiving Second Line Treatment in the Pre Novel-Agents Era: An Analysis of the 2007-2013 SEER-Medicare DatabaseMato A, Jahnke J, Li P, Mehra M, Ladage V, Mahler M, Fanning M, Doshi J, Huntington S. Characterization of Real World Survival Outcomes Among Older Adults with Chronic Lymphocytic Leukemia Receiving Second Line Treatment in the Pre Novel-Agents Era: An Analysis of the 2007-2013 SEER-Medicare Database Blood 2016, 128: 4790-4790. DOI: 10.1182/blood.v128.22.4790.4790.
  • Characterization of Real World Treatment Patterns and Outcomes Among Older Adults with Chronic Lymphocytic Leukemia in the Pre Novel-Agents Era: An Analysis of the 2007-2013 SEER-Medicare DatabaseMato A, Jahnke J, Li P, Mehra M, Ladage V, Mahler M, Huntington S, Doshi J. Characterization of Real World Treatment Patterns and Outcomes Among Older Adults with Chronic Lymphocytic Leukemia in the Pre Novel-Agents Era: An Analysis of the 2007-2013 SEER-Medicare Database Blood 2016, 128: 4773-4773. DOI: 10.1182/blood.v128.22.4773.4773.
  • Platelet Disorders: Diagnostic Tests and Their InterpretationsHuntington S, O’Hara M, Bennett J. Platelet Disorders: Diagnostic Tests and Their Interpretations 2016, 171-183. DOI: 10.1007/978-3-319-30352-9_16.
  • ME2 Medicare Part D Cost Sharing And Specialty Drug Initiation In Newly Diagnosed Chronic Myeloid Leukemia PatientsDoshi J, Li P, Huo H, Pettit A, Kumar R, Huntington S, Weiss B. ME2 Medicare Part D Cost Sharing And Specialty Drug Initiation In Newly Diagnosed Chronic Myeloid Leukemia Patients Value In Health 2016, 19: a3. DOI: 10.1016/j.jval.2016.03.035.
  • Comparative Effectiveness of Azacitidine Versus Decitabine Among Older Adults Diagnosed with Higher-Risk Myelodysplastic Syndromes (HR-MDS)Zeidan A, Long J, Hall J, Wang R, Huntington S, Abel G, Prebet T, Podoltsev N, Gross C, Gore S, Ma X, Davidoff A. Comparative Effectiveness of Azacitidine Versus Decitabine Among Older Adults Diagnosed with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Blood 2015, 126: 3285-3285. DOI: 10.1182/blood.v126.23.3285.3285.
  • Lack of Association Between Costs of Care and Overall Survival (OS) Among Medicare Beneficiaries with Myelodysplastic Syndromes (MDS) in the United States (US)Zeidan A, Wang R, Davidoff A, Gore S, Soulos P, Huntington S, Gross C, Ma X. Lack of Association Between Costs of Care and Overall Survival (OS) Among Medicare Beneficiaries with Myelodysplastic Syndromes (MDS) in the United States (US) Blood 2015, 126: 873-873. DOI: 10.1182/blood.v126.23.873.873.
  • Abstract 3430: Toxicity and long-term outcomes of elderly patients with refractory or relapsed diffuse large B cell lymphoma undergoing autologous stem cell transplantationHuntington S, Hu B, Landsburg D, Mato A, Nasta S, Schuster S, Stadtmauer E, Svoboda J. Abstract 3430: Toxicity and long-term outcomes of elderly patients with refractory or relapsed diffuse large B cell lymphoma undergoing autologous stem cell transplantation 2015, 3430-3430. DOI: 10.1158/1538-7445.am2015-3430.
  • Assessing financial toxicity in insured patients with multiple myeloma.Huntington S, Weiss B, Vogl D, Cohen A, Garfall A, Doshi J, Stadtmauer E. Assessing financial toxicity in insured patients with multiple myeloma. Journal Of Clinical Oncology 2015, 33: 6600-6600. DOI: 10.1200/jco.2015.33.15_suppl.6600.
  • A phase I trial of lenalidomide maintenance after autologous stem cell transplant (ASCT) in patients with high-risk relapsed/refractory lymphomas.Svoboda J, Strelec L, Shah N, Chong E, Montrey K, Walsh K, Huntington S, Mato A, Landsburg D, Nasta S, Schuster S. A phase I trial of lenalidomide maintenance after autologous stem cell transplant (ASCT) in patients with high-risk relapsed/refractory lymphomas. Journal Of Clinical Oncology 2015, 33: 8553-8553. DOI: 10.1200/jco.2015.33.15_suppl.8553.
  • The Impact of Marital and Socioeconomic Status on Outcomes of Patients with Acute Promyelocytic LeukemiaHuntington S, Shah N, Epstein A, Loren A. The Impact of Marital and Socioeconomic Status on Outcomes of Patients with Acute Promyelocytic Leukemia Blood 2014, 124: 1282-1282. DOI: 10.1182/blood.v124.21.1282.1282.
  • Cost-utility analysis of routine surveillance imaging of patients in first remission after treatment for diffuse large B-cell lymphoma.Huntington S, Svoboda J, Doshi J. Cost-utility analysis of routine surveillance imaging of patients in first remission after treatment for diffuse large B-cell lymphoma. Journal Of Clinical Oncology 2014, 32: 6526-6526. DOI: 10.1200/jco.2014.32.15_suppl.6526.
  • Utility assessment of interim FDG-PET/CT in frontline therapy of patients with diffuse large B-cell lymphoma (DLBCL).Huntington S, Nasta S, Schuster S, Doshi J, Svoboda J. Utility assessment of interim FDG-PET/CT in frontline therapy of patients with diffuse large B-cell lymphoma (DLBCL). Journal Of Clinical Oncology 2014, 32: 8549-8549. DOI: 10.1200/jco.2014.32.15_suppl.8549.
  • Toxicity and Response Among Octogenarians and Nonagenarians with Diffuse Large B Cell Lymphoma Treated with Rituximab-CHOP TherapyHuntington S, Sharifi M, Greer J, Morgan D, Reddy N. Toxicity and Response Among Octogenarians and Nonagenarians with Diffuse Large B Cell Lymphoma Treated with Rituximab-CHOP Therapy Blood 2010, 116: 1778-1778. DOI: 10.1182/blood.v116.21.1778.1778.

Clinical Trials

ConditionsStudy Title
Multiple MyelomaA Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
Non-Hodgkin's LymphomaA Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL)
Non-Hodgkin's LymphomaA Phase 1, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Subjects With Relapsed or Refractory T or B Cell Malignancies
Non-Hodgkin's LymphomaA Multi-center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects With Relapsed and/or Refractory Diffuse Large B Cell Lymphoma
Lymphoid LeukemiaA Phase 1b/2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies
Anus; Breast - Female; Breast - Male; Colon; Corpus Uteri; Esophagus; Hodgkin's Lymphoma; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Melanoma, skin; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach; Thyroid; Phase I; Unknown Sites; Breast; Cervix; Urinary BladderPhase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer
Non-Hodgkin's LymphomaA Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
Non-Hodgkin's LymphomaAn Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Hodgkin's Lymphoma; Lymphoid LeukemiaA Phase Ia/Ib Study of a Novel BTK Inhibitor, DTRMWXHS-12, and Combination Products, DTRM-505 and DTRM-555, in Patients With Chronic Lymphocytic Leukemia or Other B-cell Lymphomas
Non-Hodgkin's LymphomaPhase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination With Anti-Neoplastic Agents in Subjects With Non-Hodgkin Lymphoma
Non-Hodgkin's LymphomaA Phase 1-2, Open-Label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Activity of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma
Leukemia, not otherwise specified; Leukemia, other; Multiple Myeloma; Non-Hodgkin's LymphomaA Phase Ib, Multicenter Study of VOB560 in Combination With MIK665 in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma